Vectura Group plc Update on UK GSK patent litigation
13 December 2018 - 11:34PM
RNS Non-Regulatory
TIDMVEC
Vectura Group plc
13 December 2018
Update on UK GSK patent litigation
Chippenham, UK - 13 December 2018: Vectura Group plc (LSE: VEC)
("Vectura" or "the Group") reports that earlier today judgement was
handed down in the action brought against it by GlaxoSmithKline
(GSK) in the UK Courts in relation to certain additional patents
under the patent licence and option agreement with Vectura dated
5th August 2010, with the judgement overall ruling in favour of
GSK.
We are disappointed by the result and are reviewing the decision
in detail with our advisors. We will be considering our options,
which could include seeking permission to appeal.
Whilst any potential indirect effect of this on the US
proceedings pending against GSK will be considered, Vectura
believes that this will not materially affect those
proceedings.
- Ends-
For more information, please contact:
Vectura Group plc
David Ginivan - VP Corporate Communications +44 (0)7471 352 720
Julia Wilson - Director Investor Relations +44 (0)781 8430877
Consilium Strategic Communications +44 (0)20 3709 5700
Mary-Jane Elliott / Jessica Hodgson / Susan Stuart / David Daley
Forward-looking statements
This press release contains forward-looking statements,
including statements about the discovery, development and
commercialisation of products. Various risks may cause Vectura's
actual results to differ materially from those expressed or implied
by the forward-looking statements, including: adverse results in
clinical development programmes; failure to obtain patent
protection for inventions; commercial limitations imposed by
patents owned or controlled by third parties; dependence upon
strategic alliance partners to develop and commercialise products
and services; difficulties or delays in obtaining regulatory
approvals to market products and services resulting from
development efforts; the requirement for substantial funding to
conduct research and development and to expand commercialisation
activities; and product initiatives by competitors. As a result of
these factors, prospective investors are cautioned not to rely on
any forward-looking statements. We disclaim any intention or
obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
otherwise.
About Vectura
Vectura is an industry-leading inhaled product formulation,
device design and development business offering a uniquely
integrated inhaled drug delivery platform. We develop inhalation
products to help patients suffering from airways diseases.
Vectura has eight key inhaled, two non-inhaled and ten oral
products marketed by partners with growing global royalty streams,
and a diverse partnered portfolio of drugs in clinical development.
Our partners include Hikma, Novartis, Sandoz, Mundipharma, Kyorin,
Baxter, GSK, UCB, Ablynx, Bayer, Chiesi, Almirall, Janssen, Dynavax
and Tianjin KingYork.
Vectura's strategy is to fully leverage its differentiated
technology and skills, maximising value by enhancing the delivery
and performance of inhaled products and through the development of
high-quality generic alternatives to branded therapies.
For further information, please visit Vectura's website at
www.vectura.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAUOUURWKAUAAA
(END) Dow Jones Newswires
December 13, 2018 07:34 ET (12:34 GMT)
Vectura (LSE:VEC)
Historical Stock Chart
From Apr 2024 to May 2024
Vectura (LSE:VEC)
Historical Stock Chart
From May 2023 to May 2024